However, the continuous development of molecularly targeted drugs displaying higher selectivity, coupled with additional mechanistic studies and advances in profiling the signaling networks of cancer cells, should make it possible to exploit deregulation of the PI3K/Akt/mTOR cascade to achieve more effective and less toxic therapies for AML. The gene discussed is PIK3CD; the disease is cancer.